Biopharmaceutical ingredients will be a separate business area with effect from 2007, spanning sales of recombinant ingredients and new technologies to the biopharmaceutical industry.
Up to and including 2006, these have been reported as part of the ‘Technical enzymes’ business area and include sales from Novozymes Biopharma in Sweden and the two companies acquired by Novozymes in this area in 2006: Delta Biotechnology Ltd in the UK and GroPep Ltd in Australia. Sales totalled DKK 134 million in 2006.
Developments in 2007 will be significantly affected by the full-year effect of the acquisitions made, and the area is expected to grow by 100%.
